surmount-1 tirzepatide non-diabetic obesity weight loss trial Tirzepatide for Obesity: Highlights from the SURMOUNT-1 Effect of Tirzepatide on Body

Diplomate of the American Board of Obesity Medicine

All-inclusive pricing covers consultations, medication at all dose levels, supplies, and ongoing support

INDICATION AND SAFETY SUMMARY WITH WARNINGS Zepbound (ZEHP-bownd) is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off

With tirzepatide, it often occurs around month 16 to 18

Abstract Aims The objective was to assess weight reduction at Weeks 24 and 72 in participants treated with tirzepatide based on weight reduction response after 12 weeks of treatment in the SURMOUNT1 trial

A 0.3 mL syringe with half-unit markings can measure 18.5 or 19 units with reasonable precision